Company News - CITIC Securities (06030.HK) reported a revenue of RMB 74.83 billion for the fiscal year 2025, representing a year-on-year increase of 28.75%, and a net profit of RMB 30.05 billion, up 38.46% year-on-year [2] - CITIC Bank (00998.HK) announced a total revenue of RMB 212.48 billion for 2025, a slight decrease of 0.55% year-on-year, while net profit increased by 2.98% to RMB 70.62 billion [2] - Beijing North Star Industrial (00588.HK) expects to continue reporting losses for the fiscal year ending December 31, 2025 [3] - Yuexiu Property (00123.HK) reported a cumulative contract sales amount of approximately RMB 106.21 billion for 2025, a decline of about 7.3% year-on-year, achieving 88.1% of its sales target [3] - Jiao Ge Peng You Holdings (01450.HK) achieved a total GMV of approximately RMB 6.49 billion in Q4 2025, a year-on-year increase of about 4.34%, with a cumulative GMV of RMB 16.02 billion for the year, up 6.23% [3] - Sai Jing Technology (00580.HK) anticipates a revenue of approximately RMB 2.25 billion for 2025, reflecting a year-on-year increase of about 40% due to increased revenue from flexible transmission business [3] - China General Nuclear Power New Energy (01811.HK) reported a cumulative power generation of 19,000 GWh for 2025, a decrease of 0.8% year-on-year, with variations in different energy sources [3] - Morning News Technology (02000.HK) reported an unaudited revenue of HKD 397 million for 2025, a decrease of 7.4% year-on-year [3] Financing and Buyback Activities - Chow Tai Fook Enterprises (00659.HK) applied for the registration of debt financing instruments totaling no more than RMB 5 billion [7] - Tencent Holdings (00700.HK) repurchased 1.006 million shares at a cost of approximately HKD 636 million, with repurchase prices ranging from HKD 626 to HKD 638 [7] - Xiaomi Group-W (01810.HK) repurchased 4 million shares for approximately HKD 151 million, with repurchase prices between HKD 37.61 and HKD 42.50 [7] Research and Development - Hutchison China MediTech (00013.HK) announced the publication of SACHI III study results in The Lancet [4] - Laka Pharmaceuticals-B (02105.HK) had its clinical trial application for the new drug LAE118 accepted by the U.S. FDA [5] Other News - Yuanxu Technology (08637.HK) announced a short suspension of trading starting January 14, pending the release of insider information [6] - Haidilao (06862.HK) redeemed USD 600 million of its 2.150% notes due in 2026 [2]

来凯医药-B（02105）盘初涨近7%，截至发稿，股价上涨5.95%，现报14.24港元，成交额1561.68万港 元。 1月14日， 来凯医药宣布，美国食品药品监督管理局（FDA）已经受理LAE118的新药临床试验申请 （IND）。LAE118是来凯自主研发的一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA突变的实 体瘤患者。PI3Kα突变在乳腺癌、结直肠癌、肺癌、子宫内膜癌和其它癌症患者中较为常见。目前全球 已获批的PI3Kα抑制剂对突变型没有选择性， 因对野生型有很强的活性而耐受性较差，且易产生耐药 性。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 来凯医药-B（02105）盘初涨近7%，截至发稿，股价上涨5.95%，现报14.24港元，成交额1561.68万港 元。 1月14日， 来凯医药宣布，美国食品药品监督管理局（FDA）已经受理LAE118的新药临床试验申请 （IND）。LAE118是来凯自主研发的一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA突变的实 体瘤患者。PI3Kα突变在乳腺癌、结直肠癌、肺癌、子宫内膜癌和其它癌症患者中较为常见。目前全球 已获 ...

消息面上，1月14日， 来凯医药宣布，美国食品药品监督管理局（FDA）已经受理LAE118的新药临床 试验申请（IND）。LAE118是来凯自主研发的一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA 突变的实体瘤患者。PI3Kα突变在乳腺癌、结直肠癌、肺癌、子宫内膜癌和其它癌症患者中较为常见。 目前全球已获批的PI3Kα抑制剂对突变型没有选择性， 因对野生型有很强的活性而耐受性较差，且易产 生耐药性。 智通财经APP获悉，来凯医药-B(02105)早盘涨近7%，截至发稿，涨5.88%，报14.23港元，成交额934.24 万港元。 ...

Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) experienced a significant increase, rising nearly 7% in early trading, with a current price of 14.23 HKD and a trading volume of 9.34 million HKD, following the announcement of the acceptance of their new drug clinical trial application by the FDA for LAE118 [1] Group 1: Company Developments - Lai Kai Pharmaceutical announced that the FDA has accepted the Investigational New Drug (IND) application for LAE118 on January 14 [1] - LAE118 is a novel PI3Kα pan-mutant selective inhibitor developed by Lai Kai, aimed at treating patients with PIK3CA mutations in solid tumors [1] Group 2: Industry Context - PI3Kα mutations are commonly found in patients with breast cancer, colorectal cancer, lung cancer, endometrial cancer, and other cancers [1] - Currently approved PI3Kα inhibitors globally lack selectivity for mutant types, exhibiting strong activity against wild types, which leads to poor tolerability and a high likelihood of developing resistance [1]

Core Viewpoint - The announcement highlights that the U.S. Food and Drug Administration (FDA) has accepted the clinical trial application for LAE118, a novel PI3Kα pan-mutant selective inhibitor aimed at treating patients with PIK3CA-mutated solid tumors [1] Company Summary - The company is committed to collaborating closely with regulatory authorities to complete the relevant application for LAE118 [1] - The company has a proven track record in clinical development and licensing with LAE002 (afuresertib), reinforcing its dedication to providing precision treatments for cancer patients in need of new therapeutic options [1] Industry Summary - LAE118 represents a new therapeutic approach in the oncology sector, specifically targeting PIK3CA mutations, which are prevalent in various solid tumors [1]

LAE118是一种新型PI3Kα泛突变选择性抑制剂。作为针对PIK3CA突变实体瘤的新型疗法，集团正积极 推进此候选药物进入临床研究。 智通财经APP讯，来凯医药-B(02105)发布公告，美国食品药品监督管理局已经受理 LAE118的新药临床 试验申请。LAE118是一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA突变的实体瘤患者。公司 将与监管机构紧密合作以完成相关申请。凭借其在临床开发和对外授权 LAE002(afuresertib)的良好及已 验证的实绩，公司致力于为需要新型治疗方案的癌症患者提供这种精准治疗。 ...

Core Viewpoint - The company has announced that the U.S. Food and Drug Administration (FDA) has accepted the clinical trial application for LAE118, a novel PI3Kα pan-mutant selective inhibitor aimed at treating patients with PIK3CA-mutant solid tumors [1] Group 1: Drug Development - LAE118 is a new type of PI3Kα pan-mutant selective inhibitor [1] - The company is actively advancing this candidate drug into clinical research as a novel therapy for PIK3CA-mutant solid tumors [1] - The company aims to provide precision treatment options for cancer patients in need of new therapeutic solutions [1] Group 2: Regulatory Collaboration - The company will work closely with regulatory authorities to complete the relevant application [1] - The company has a proven track record in clinical development and licensing, particularly with LAE002 (afuresertib) [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本 公 司 將 與 監 管 機 構 緊 密 合 作 以 完 成 相 關 申 請 。 憑 藉 其 在 臨 床 開 發 和 對 外 授 權 LAE 002 (afuresertib)的良好及已驗證的實績，本公司致力於為需要新型治療方案的 癌症患者提供這種精准治療。 關於LAE118 LAE118是一種新型PI3Kα泛突變選擇性抑制劑。作為針對PIK3CA突變實體瘤的新 型療法，本集團正積極推進此候選藥物進入臨床研究。 – 1 – 風險提示 LAE118最終不一定能夠成功開發及商業化。本公司股東及潛在投資者於買賣本公 司證券時務請審慎行事。 （於開曼群島註冊成立之有限公司） （股份代號：2105） 來凱醫藥有限公司 Laekna, Inc. 自願公告 美國食品藥品監督管理局受理LAE118新藥臨床試驗申請 本 公 告 由 來 凱 醫 藥 有 限 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 來凱醫藥有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股 ...

Major Events - Black Sesame Intelligence (02533) plans to acquire and increase its stake to 60% in Zhuhai Yizhi Electronic Technology, aiming to establish a full-scenario ecosystem for AI chips [1] - China Biopharmaceutical (01177) has completed the enrollment of the first patient in the Phase III clinical trial of its self-developed TDI01 "ROCK2 inhibitor" for the treatment of idiopathic pulmonary fibrosis [1] - Cao Cao Travel (02643) sees a positive outlook and its controlling shareholder voluntarily extends the lock-up commitment [1] - Laike Pharmaceutical-B (02105) has completed the first dosing of the Phase I single-dose escalation study for LAE103 [1] - VALA (02051) has launched its new model, Vala Home, and is collaborating with Ruichi Automobile to enhance production capacity and delivery systems [1] Operating Performance - BYD Company (01211) expects to achieve approximately 4.6024 million units in new energy vehicle sales for 2025, representing a year-on-year increase of 7.73% [1] - Geely Automobile (00175) reported total vehicle sales of 236,800 units in December, a year-on-year increase of approximately 13% [1] - NIO Inc. (09866) delivered 48,100 vehicles in December, setting a new monthly record with a year-on-year increase of 54.6% [1] - Great Wall Motors (02333) anticipates sales of approximately 1.3237 million units for 2025, reflecting a year-on-year growth of 7.33% [1] - Xpeng Motors (09868) achieved a total delivery of 429,400 vehicles for the entire year of 2025, marking a year-on-year increase of 126% [1] - China Power (02380) reported a total consolidated electricity sales volume of 10.0997 million megawatt-hours in November, an increase of 15.38% year-on-year [1] - Li Auto (02015) delivered 44,200 new vehicles in December, a year-on-year decrease of 24.44% [1]